Evidence map›Paper›PMID 26637806›Full record

ArticleOncotarget2016

Molecular heterogeneity of glioblastomas: does location matter?

Emilie Denicolaï, Emeline Tabouret, Carole Colin, Philippe Metellus, Isabelle Nanni, Celine Boucard, Aurélie Tchoghandjian, David Meyronet, Nathalie Baeza-Kallee, Olivier Chinot and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Emilie DenicolaïAix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.
Emeline TabouretAix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.
Carole ColinAix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.
Philippe MetellusAP-HM, Timone Hospital, Department of Neuro-Surgery, Marseille, 13385, France.
Isabelle NanniAP-HM, North Hospital, Transfer Laboratory, Marseille, 13915, France.
Celine BoucardAP-HM, Timone Hospital, Department of Neuro-Oncology, Marseille, 13385, France.
Aurélie TchoghandjianAix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.
David MeyronetHospices Civils de Lyon, Centre de Pathologie et de Neuropathologie Est, Lyon, 69677, France.
Nathalie Baeza-KalleeAix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.
Olivier ChinotAix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.
Dominique Figarella-BrangerAix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.
Aix-Marseille Université · FRHôpital de la Timone · FRInserm · FRHospices Civils de Lyon · FRLyon Genou Centre Albert Trillat · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastomas in adults are highly heterogeneous tumors that can develop throughout the brain. To date no predictive-location marker has been identified. We previously derived two glioblastoma cell lines from cortical and periventricular locations and demonstrated distinct transcriptomic profiles. Based on these preliminary results, the aim of this study was to correlate glioblastoma locations with the expression of ten selected genes (VEGFC, FLT4, MET, HGF, CHI3L1, PROM1, NOTCH1, DLL3, PDGFRA, BCAN). Fifty nine patients with newly diagnosed glioblastomas were retrospectively included. Tumors were classified into cortical and periventricular locations, which were subsequently segregated according to cerebral lobes involved: cortical fronto-parietal (C-FP), cortical temporal (C-T), periventricular fronto-parietal (PV-FP), periventricular temporal (PV-T), and periventricular occipital (PV-O). Gene expression levels were determined using RT-qPCR. Compared to cortical glioblastomas, periventricular glioblastomas were characterized by a higher expression of two mesenchymal genes, VEGFC (p = 0.001) and HGF (p = 0.001). Among cortical locations, gene expressions were homogeneous. In contrast, periventricular locations exhibited distinct expression profiles. PV-T tumors were associated with higher expression of two proneural and cancer stem cell genes, NOTCH1 (p = 0.028) and PROM1 (p = 0.033) while PV-FP tumors were characterized by high expression of a mesenchymal gene, CHI3L1 (p = 0.006). Protein expression of NOTCH1 was correlated with RNA expression levels. PV-O glioblastomas were associated with lower expression of VEGFC (p = 0.032) than other periventricular locations, whereas MET overexpression remained exceptional. These data suggest a differential gene expression profile according to initial glioblastoma location.

Indexed as

Genetic HeterogeneityAdultAgedBiomarkers, TumorBrainBrain NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGlioblastomaHumansImmunohistochemistryMaleMiddle AgedRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionBiomarkers, Tumorglioblastomamesenchymal profileproneural profiletumor location

Identifiers

PMID26637806
PMCPMC4808041
OpenAlexW2254529306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.